Phaseline

Targets › COMT

COMT (Catechol O-methyltransferase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Dec 2029.

Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOPA, alpha-methyl DOPA and isoproterenol. (UniProt, P21964)

Open in Phaseline: the race on COMT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Satish R. RajEntacapone
Catechol O-methyltransferase inhibitor
COMTPhase 1TachycardiaDec 2029

Conditions

Tachycardia (1)

Modalities

mixed (1)

Companies

Satish R. Raj (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.